Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation

Autor: Lemoine A, Azoulay D, Jm, Gries, Ashley Dennison, Castaing D, Fredj G, Debuire B, Fp, Guengerich, Beaune P, Bismuth H

Publikováno v: Europe PubMed Central

Cytochrome P-450 3A metabolizes CsA into several metabolites with very limited pharmacological activity and toxicity. In 40 liver donors, the relative concentrations of P-450 3A was assessed by immunoblot analysis using a specific monoclonal antibody

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5efee63847495e59333419227c953882
https://pubmed.ncbi.nlm.nih.gov/8279011

Sentinel Dosing-Time for a Risk-Based Approach?

Autor: Bonate PL, Rogge M, Gries JM, Prokopienko AJ, Pai SM

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Nov 24. Date of Electronic Publication: 2024 Nov 24.

Blueprint for antibody biologics developability.

Autor: Mieczkowski C; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Zhang X; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Lee D; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Nguyen K; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Lv W; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Wang Y; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Zhang Y; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Way J; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Gries JM; President, Discovery Research, Hengenix Biotech, Inc, Milpitas, CA, USA.

Publikováno v: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2185924.

Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA.

Autor: Pai SM, Othman AA, Rusch L, Masters JC, Greene D, Rogge M, Gries JM, Clementi W, Kumar P, Younis I, Salem AH, Gaynes BI, Pastino G, Derendorf H

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Mar; Vol. 61 (3), pp. 277-279. Date of Electronic Publication: 2021 Jan 27.

Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.

Autor: Rodriguez-Torres M; Fundacion de Investigación de Diego, Santurce, Puerto Rico. fdciondeinvest@aol.com, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M, Dieterich D, Wang K, Gries JM, Hoggard PG, Back D

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2005 Oct; Vol. 49 (10), pp. 3997-4008.